biotech investing argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026
biotech investing argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
biotech investing argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
biotech investing argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
biotech investing argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
biotech investing argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
biotech investing Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
biotech investing argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
biotech investing argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026
biotech investing argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline
biotech investing argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update
biotech investing argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
Edgewater Wireless Brings Growing Semiconductor Momentum and Dual-Use Innovation to Canada's Semiconductor Symposium 2026
Brixton Metals Reports 97.0% Gold Recovery in Initial Metallurgical Work from the Trapper Gold Target
GoldInxs Commences Maiden Drill Program at the Fishpot Project, Testing Multiple Gold-Silver and Copper-Gold Targets
